Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580032 · ClinicalTrials.gov registry record
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
A clinical trial of Growth Disorder and Growth Hormone Deficiency in Children, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 252
- Enrollment target
- 20
- Study locations
NCT02580032 is a study of Growth Disorder and Growth Hormone Deficiency in Children that has completed, run by Novo Nordisk A/S. The registered enrollment target is 252 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02580032, a study of Growth Disorder and Growth Hormone Deficiency in Children, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD).
Conditions Studied
Interventions
- OTHER No treatment given
Study Locations (20)
New York
- Novo Nordisk Investigational Site - Albany
- Novo Nordisk Investigational Site - Buffalo
- Novo Nordisk Investigational Site - Mineola
- Novo Nordisk Investigational Site - New York
- Novo Nordisk Investigational Site - Spring Valley
Florida
- Novo Nordisk Investigational Site - Margate
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Tallahassee
Arizona
- Novo Nordisk Investigational Site - Phoenix
Colorado
- Novo Nordisk Investigational Site - Centennial
Delaware
- Novo Nordisk Investigational Site - Wilmington
Georgia
- Novo Nordisk Investigational Site - Atlanta
Illinois
- Novo Nordisk Investigational Site - Wheaton
Iowa
- Novo Nordisk Investigational Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2018-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02580032
The ClinicalTrials.gov registry entry for NCT02580032 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Growth Disorder appearing as the primary indexed condition, and to 1 intervention - of which No treatment given is the first listed.
NCT02580032 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02580032 about?
NCT02580032 is a clinical study titled "Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)". This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood ...
What is the current status of trial NCT02580032?
This trial is currently completed. The enrollment target is 252 participants. The study started on 2015-10-05. Estimated completion is 2018-05-14.
What conditions does trial NCT02580032 study?
This clinical trial studies the following conditions: Growth Disorder, Growth Hormone Deficiency in Children.
What interventions are being tested in trial NCT02580032?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT02580032?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02580032 being conducted?
This trial has 20 study locations across Arizona, Colorado, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.